Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
Podcast: Expert Talks About 'Kanna,' The Legal African Succulent That Elevates Awareness, Concentration And More
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Russell Newcombe Dies - Legacy Of UK's Longtime Harm Reduction Advocate, Committed Drug Researcher
Psychedelics Reform Update: Missouri's $10M Budget, Maine's & Maryland's Study Groups, Oregon's Re-Crim And More
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Two Top Biotechs Forge MDMA Supply Deals For An Expanding Research Field
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
VA Calls For Amending Medical Marijuana Bill, Rejects Psychedelics Proposal
Congress Discusses Remaining FY2024 Spending Bill With Provisions On Cannabis Sales And Psychedelic Clinical Trials
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More